Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19977257 | 0.89 | HTR2A (0.35) | HTR2AHTR2CHTR2BCYP2D6 | |
| SCHEMBL22482269 | 0.73 | CTNNB1 (0.42) | HTR2AHTR2CHTR2B | |
| SCHEMBL2633503 | 0.73 | CTNNB1 (0.42) | HTR2AHTR2CHTR2B | |
| SCHEMBL10157959 | 0.73 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL5023473 | 0.73 | CTNNB1 (0.46) | KDM4E | |
| SCHEMBL31061889 | 0.73 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL21019952 | 0.71 | KDM4E (0.35) | KCNH2KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL13262203 | 0.70 | KDM4E (0.43) | KDM4EACHE | |
| SCHEMBL20403046 | 0.70 | ESR1 (0.30) | — | |
| SCHEMBL2629597 | 0.68 | HDAC3 (0.45) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851119-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851119-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | HTR1A 4609/4885HTR1D 4268/4885KCNH2 3557/4885 |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | CD22, BRDT, BCR | HTR1A 4609/4885HTR1D 4268/4885KCNH2 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.